IDEXX Laboratories, Inc.

NASDAQ:IDXX

Medical - Diagnostics & Research

Healthcare
$698.47 +2.26%

+$12.33 today

Market cap
$55.03B
Beta
1.54
P/E (TTM)
40.8
EPS (TTM)
$13.67
52W Low $506.91High $769.98

Volume 0.37M

Average 0.58M

IDXX EBITDA Margin

EBITDA as a percentage of revenue.

IDEXX Laboratories, Inc.NASDAQ: IDXX

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin narrows to 32.9%

EBITDA Margin was 32.9% in Q3 FY2026, down 2.6 pp from a year earlier. On a trailing-twelve-month basis it was 34.9%, up 0.0 pp year over year. Over 3 fiscal years it widened by 4.9 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 11 analysts of 35.2% for the fiscal year ending Dec 2026, up from 35.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
32.9%-5.6 pp QoQ
Last fiscal yearDec 2025
35.0%+2.3 pp YoY
LTMSep 2026
34.9%+0.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.6 pp-0.7 pp+1.9 pp
1 year+2.3 pp+0.2 pp-2.1 pp
3 years+4.9 pp+2.7 pp-2.2 pp
5 years+5.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
35.0%
Year-over-year change
+2.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How IDXX compares with its peers on the latest reported figures

  • IDXX's LTM Sep 2026 EBITDA Margin of 34.9% is the 2nd highest of the 5 companies compared; the peer median is 17.1%.
  • Its year-over-year change of +0.0 pp is the 2nd highest of 5, against a peer median of -3.6 pp.
  • Over three fiscal years its change of +4.9 pp compares with a peer median of +2.6 pp.
IDXX Competitors Peer median
EBITDA Margin for IDXX and competitors
Company Period LTM level YoY 3-year change
ZTSZoetis Inc.LTM Jun 202642.0% -1.1 pp+1.4 pp
IDXXIDEXX Laboratories, Inc.LTM Sep 202634.9% +0.0 pp+4.9 pp
MRKMerck & Co., Inc.LTM Jun 202621.0% -18.3 pp+7.6 pp
ELANElanco Animal Health IncorporatedLTM Sep 202613.2% -6.2 pp-5.3 pp
NEOGNeogen CorporationLTM Aug 202611.9% +111.0 pp+3.8 pp
Peer median (excluding IDXX) 17.1%-3.6 pp+2.6 pp

Competitors are the stored peer set for IDXX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.22B3.37B3.66B3.9B4.3B
Cost of Revenue1.33B1.36B1.47B1.52B1.64B
Gross Profit1.89B2B2.19B2.38B2.66B
Gross Margin58.8%59.5%59.8%61.0%61.8%
Research & Development161.01M254.82M190.95M219.79M251.21M
Selling, General & Admin796.4M850.75M901.89M1.03B1.05B
Operating Expenses957.4M1.11B1.09B1.25B1.3B
Depreciation & Amortization104.6M111.9M114.91M129.94M145.18M
EBITDA1.04B1.01B1.22B1.28B1.51B
EBITDA Margin32.3%30.1%33.3%32.7%35.0%
Operating Income932.03M898.77M1.1B1.13B1.36B
Operating Margin29.0%26.7%30.0%29.0%31.6%
Interest Income434K1.07M5.63M12.7M2.42M
Interest Expense29.81M39.86M41.58M31.21M38.27M
Other Income / Expenses(29.37M)(38.79M)(35.95M)(18.51M)(35.84M)
Income Before Tax902.65M859.97M1.06B1.11B1.32B
Pre-Tax Margin28.1%25.5%29.0%28.5%30.8%
Income Tax Expense157.81M180.88M216.13M221.96M264.73M
Net Income744.85M679.09M845.04M887.87M1.06B
Net Margin23.2%20.2%23.1%22.8%24.6%
EPS (Basic)8.748.1210.1710.7713.17
EPS (Diluted)8.608.0310.0610.6713.08
Weighted Avg Shares85.2M83.62M83.07M82.47M80.1M
Weighted Avg Shares (Diluted)86.57M84.6M83.98M83.25M80.68M

IDEXX Laboratories, Inc.

NASDAQ:IDXX

Intrinsic Alpha fair value

Locked

Current Price

$698.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.